Tixagevimab/cilgavimab in ANCA-associated vasculitis: a prospective observational study

Clin Exp Rheumatol. 2024 Apr;42(4):937. doi: 10.55563/clinexprheumatol/xexruk. Epub 2023 Oct 23.

Authors

Mariia Litvinova¹, Nikolay Bulanov², Pavel Novikov¹, Sergey Moiseev³

Affiliations

¹ Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
² Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia. nmbulanov@gmail.com.
³ Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University (Sechenov University), Moscow; and Lomonosov Moscow State University, Moscow, Russia.

PMID: 37877380
DOI: 10.55563/clinexprheumatol/xexruk

No abstract available

Publication types

Observational Study
Letter

MeSH terms

Aged
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
Antibodies, Monoclonal, Humanized* / adverse effects
Antibodies, Monoclonal, Humanized* / therapeutic use
Female
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use
Male
Middle Aged
Prospective Studies
Time Factors
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents